The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review
et al., Medicine,
Systematic review of 3 VV116 studies with 1,044 participants. Authors conclude that VV116 had minimal adverse events and was not inferior in symptomatic alleviation when compared with paxlovid. Authors note that more research into the safety and efficacy of VV116 is needed, and more elderly and critically ill patients with COVID-19 should be included.
See Ma et al.
for another review covering deuremidevir for COVID-19.
Xiao et al., 7 Jul 2023, peer-reviewed, 6 authors, trial PROSPERO CRD42023391130
Systematic Review and Meta-Analysis
The safety and efficacy of oral antiviral drug
VV116 for treatment of COVID-19
wCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 01/29/2024
A systematic review
Ningkun Xiao, MDa,* , Xinlin Huang, MDa, Xiaotian Kang, Bachelorb, Wanli Zang, MDc, Bo Li, MDd,
Sergey Kiselev, PhDa
Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-
19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic
review to assess the safety and efficacy of VV116.
Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of
March 23, to identify pertinent studies.
Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental
groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the
nirmatrelvir-ritonavir control group in alleviating major symptoms.
Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number
of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate
symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted
in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical
Abbreviations: AEs = adverse events, AUC = concentration-time curve, Cmax = the maximum measured plasma concentration,
COVID-19 = corona virus disease 2019, NR = nirmatrelvir/ritonavir, PEDro = Physiotherapy Evidence Database scale, SARSCoV-2 = severe acute respiratory syndrome coronavirus 2.
Keywords: COVID-19, oral antiviral drug, public health, vaccines, VV116
have high spike protein mutation rates. There is a higher probability of vaccine breakthrough rates and widespread escape
from existing neutralizing antibodies,[8,9] more specifically, The
BQ and XBB subvariants of SARS-CoV-2 Omicron are currently
expanding rapidly, and BQ.1, BQ.1.1, XBB, and XBB.1 are the
most resistant SARS-CoV-2 variations to date, which poses
a huge challenge to the immune protection of the majority of
the population and a threat to worldwide health endeavors.
Consequently, adjunct medications have become increasingly
important for safeguarding global health.
The U.S. Food and Drug Administration has approved 2 oral
antiviral drugs for the treatment of mild to moderate COVID-19
outpatients at risk of progression to severe COVID-19: Pfizer’s
PF-07321332 (nirmatrelvir/ritonavir, paxlovid)[11,12] and Merck’s
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Vaccines and treatments are complementary. All practical, effective, and safe
means should be used based on risk/benefit analysis. No treatment, vaccine, or
intervention is 100% available and effective for all current and future
variants. We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC
provide treatment protocols.